Patrys picks up third US patent for PAT-SM6

Patrys (ASX:PAB) has been granted a third US patent protecting its anticancer candidate PAT-SM6.

The US Patent and Trademark Office has accepted Patrys’s application for a patent entitled ‘Adenocarcinoma specific antibody SAM-6, and uses thereof’.

The claims cover a method of treating various cancers. It is valid through to November 2024.

The company has also previously secured a US patent covering the mechanism of action behind PAT-6, as well as an Australian patent covering methods of use of the treatment in applications including multiple myeloma.

Patrys now has eight patents in the US, Australia, Europe and Japan, and has more applications pending in Canada, Europe and the US.

PAT-SM6 is preparing to commence a clinical trial involving using the drug in combination with proteosome inhibitor carfilzomib as a treatment for multiple myeloma.

Last month, the company revealed that a patient granted permission to use PAT-SM6 on an individual treatment basis responded well to a combination therapy involving PAT-SM6, proteosome inhibitor Velcade and Revlimid.

Patrys (ASX:PAB) shares were trading unchanged at $0.033 as of around 1.30 pm on Wednesday.